Antegren AN100226: Began a Phase I trial in the U.K. to establish safety and pharmacokinetics in 36 healthy volunteers

Athena Neurosciences Inc. (ATHN), South San Francisco Product: Antegren AN100226, humanized monoclonal directed against alpha-4-beta-1 integrin expressed on white blood cells Indication: Prevent mi...